We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Elective surgery

10 July 2014 By Robert Cyran

The drugmaker’s conservative fiscal ways left it vulnerable to Valeant’s hostile $51 bln bid. Additional cost-cutting and buybacks is a persuasive standalone response. Behind door number three could be a bold acquisition. Allergan shareholders are likely to be spoiled for choice.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)